Charles River Laboratories International (CRL) could be a good pick for your portfolio, with its high cash yield, good fundamentals, and discounted valuation. Companies like this can use cash to fuel additional revenue growth, or simply pay their shareholders through dividends or buybacks. Despite a 2.6% organic revenue decline in Q4 2025, Charles River is strengthening its core. While CRL stock may be a compelling investment opportunity, it’s always helpful to be aware of a stock’s history of drawdown. For more details and our view, see Buy or Sell CRL Stock.

Source: International New York Times February 28, 2026 15:03 UTC